"With Inari as the mechanical thrombectomy leader in pulmonary embolism (PE) and deep vein thrombosis (DVT), Inari's products could now bolster the neurovascular subsegment that represents a $1.3 ...

Inari Medical, Inc. NARI is well-poised for growth on the back of a huge market opportunity for its products and its commitment to understanding the venous system. However, the company’s dependency on ...

Key barriers in adhering to anticoagulation guidelines included uncertainty about its choice, established practices, and the ...

Inari Medical’s product portfolio includes medical devices that treat pulmonary embolism, deep vein thrombosis, in-stent thrombosis and arteriovenous fistula. Stryker said the products are “hi ...

Outpatient management of patients with cancer-associated pulmonary embolism (PE) may be a feasible, safe approach with low short-term rates of recurrent venous thromboembolism (VTE), major bleeding, ...

It includes mechanical thrombectomy solutions for peripheral vascular diseases such as deep vein thrombosis and pulmonary embolism. “The acquisition of Inari expands Stryker's portfolio to ...

Inari is poised to enhance Stryker's footprint ... These solutions are designed to treat peripheral vascular conditions such as pulmonary embolism and deep vein thrombosis. They claim to remove ...

Inari shareholders are getting a fair price ... and has not really been a player in venous markets like pulmonary embolism (or PE), deep vein thrombosis (or DVT), limb ischemia, and the like ...

Inari, which was founded in 2011 ... solutions for peripheral vascular diseases such as deep vein thrombosis and pulmonary embolism. Each year, VTE impacts up to 900,000 lives in the United ...